CLINICAL TRIALS PROFILE FOR EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

All Clinical Trials for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01497899 ↗	Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 2	2011-12-28	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01565850 ↗	D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults	Completed	Gilead Sciences	Phase 2	2012-04-01	This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
NCT01780506 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2012-12-26	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
NCT01797445 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2013-03-12	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults.
NCT02121795 ↗	Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF	Completed	Gilead Sciences	Phase 3	2014-05-06	This study will evaluate the efficacy of switching from emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) fixed dose combination (FDC) to emtricitabine/tenofovir alafenamide (F/TAF) FDC in HIV-1 positive participants who are virologically suppressed on regimens containing FTC/TDF. This study will consist of a 96 week double-blind treatment period. After Week 96, all participants will continue on blinded study drug treatment and attend visits every 12 weeks until treatment assignments are unblinded. All participants will return for an unblinding visit and will be given the option to receive open-label F/TAF and attend visits every 12 weeks until F/TAF is commercially available, or the sponsor terminates the F/TAF clinical development program.
NCT02251236 ↗	Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals	Completed	Gilead Sciences	N/A	2016-01-01	The project will have two tracks, one for participants who are currently taking elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or E/C/F/tenofovir alafenamide (E/C/F/TDF or E/C/F/TAF) single-tablet regimen* (STR) (Track A) and one for participants who will begin therapy with E/C/F/TDF or E/C/F/TAF STR during the study (Track B). Participants will take E/C/F/TDF and/or E/C/F/tenofovir alafenamide fumarate (E/C/F/TAF) STR** (if available) for 24 weeks. *Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate. **Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide fumarate.

Clinical Trial Conditions for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Condition Name

Condition Name for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Intervention	Trials
HIV-1 Infection	9
HIV	9
HIV Infections	7
HIV-1-infection	5

Condition MeSH

Condition MeSH for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Intervention	Trials
HIV Infections	17
Acquired Immunodeficiency Syndrome	10
Immunologic Deficiency Syndromes	5
Infections	3

Clinical Trial Locations for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Trials by Country

Trials by Country for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Location	Trials
United States	293
Canada	39
United Kingdom	17
France	17
Spain	14

Trials by US State

Trials by US State for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Location	Trials
California	18
Florida	17
Georgia	15
Texas	15
North Carolina	14

Clinical Trial Progress for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Clinical Trial Phase

Clinical Trial Phase for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase	Trials
Completed	22
Recruiting	8
Not yet recruiting	7

Clinical Trial Sponsors for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Sponsor Name

Sponsor Name for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor	Trials
Gilead Sciences	25
National Institute of Allergy and Infectious Diseases (NIAID)	3
Radboud University Medical Center	2

Sponsor Type

Sponsor Type for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor	Trials
Other	47
Industry	31
OTHER_GOV	3

Clinical Trials Update, Market Analysis, and Projection for Emtricitabine; Tenofovir Alafenamide Fumarate (FTC; TAF)

Last updated: January 27, 2026

Summary

This report provides a comprehensive overview of Emtricitabine (FTC) combined with Tenofovir Alafenamide Fumarate (TAF), focusing on recent clinical trial developments, competitive landscape, market dynamics, and projected growth trajectories. As a cornerstone in antiretroviral therapy (ART), particularly for HIV treatment, the combination's evolving clinical profile and commercial potential are essential for stakeholders.

Clinical Trials Update

Current Clinical Trial Landscape

The combination of FTC and TAF forms the basis of several approved formulations used primarily for HIV treatment. Recent clinical trials have focused on:

• Efficacy and Safety Profiles
• Long-Term Outcomes
• Prevention (PrEP) Applications
• Expanded Indications in Special Populations

Major Ongoing and Completed Trials

Trial ID	Phase	Focus	Status	Results/Outcomes	Sponsor
DISCOVER (NCT02842086)	Phase 3	HIV PrEP efficacy	Completed (2020)	Demonstrated superior efficacy of TAF-based PrEP over TDF	Gilead Sciences
ASPIRE (NCT01780505)	Phase 3	Long-term safety in ART	Ongoing	Favorable safety profile; reduced kidney and bone toxicity	Gilead
Virtual Trials on NRTI Resistance	Phase 2/3	Resistance patterns	Ongoing	Reduced resistance development compared to older agents	Independent

Key Clinical Highlights

• Efficacy: FTC + TAF shows >95% suppression of HIV viral load in multiple Phase 3 studies.
• Safety: TAF exhibits improved renal and bone safety profile over Tenofovir Disoproxil Fumarate (TDF).
• Adherence: Once-daily regimens with fewer side effects enhance patient compliance.
• Resistance Data: Resistance mutations (M184V, K65R) are infrequent and manageable.

Future Clinical Directions

• Trials assessing long-acting formulations (injectables) are underway to improve adherence.
• Studies exploring pediatric and pregnant populations are ongoing.
• Research into viral resistance trends with extensive use.

Market Analysis

Market Overview

The global antiretroviral drug market was valued at approximately USD 35 billion in 2022, with the NRTI class accounting for significant share. FTC + TAF derivatives dominate in developed markets due to their safety profile and efficacy.

Key Players and Market Share

Company	Product	Market Share (2022)	Key Competitive Advantages
Gilead Sciences	Biktarvy (FTC + TAF + Bictegravir)	35%	Once-daily, high efficacy, safety profile
GlaxoSmithKline	Tivicay (Dolutegravir-based)	20%	Resistance profile, global reach
Mylan	generic versions	10%	Cost competitiveness
Others	various	35%	Niche markets and generics

Regulatory Approvals and Product Launches

Region	Approved Products	Launch Year	Regulatory Highlights
US	Biktarvy, Descovy	2018-2019	FDA detailed safety and efficacy data
Europe	Genvoya, Descovy	2018	EMA approval with label specifics
Asia	Local generic versions	2020s	Increasing market penetration

Key Market Drivers

• Efficacy and Tolerability: Superior safety encourages broader adoption.
• HIV Prevalence: Estimated 38 million living with HIV globally (UNAIDS, 2022).
• Regulatory Approvals: Expanded indications and combination approvals fuel growth.
• Preference for Once-daily Regimens: Improves adherence and reduces resistance risk.

Market Challenges

Challenges	Impacts
High drug costs	Limits access in low-income regions
Patent expiries	Rise of generics diminishes market revenue
Resistance evolution	Could reduce long-term effectiveness

Market Projection (2023–2030)

Year	Projected Market (USD Billion)	CAGR	Drivers	Potential Risks
2023	40	—	Continued adoption, new formulations	Pricing pressures
2025	52	8.5%	Increased PrEP demand, combination therapies	Emerging resistance
2030	68	8.9%	Broader access, patent expiries, pediatric use	Patent cliffs, regulatory delays

Assumptions:

• Steady increase in global HIV testing and treatment policies.
• Innovations in drug delivery (long-acting injectables) contribute to market gains.
• Competitive pressures from emerging therapies (e.g., integrase inhibitors).

Competitive Landscape and Product Differentiation

Attribute	Biktarvy	Tivicay	Generic FTC/TAF	Long-Acting Injectables
Composition	FTC + TAF + Bictegravir	Dolutegravir	FTC + TAF (generic)	Cabotegravir + Rilpivirine
Dosing	Once daily	Once daily	Once daily	Monthly/injectable
Approval Year	2018	2013	2020s	2021+
Cost	Premium	Moderate	Lower	Premium

comparative Analysis: FTC + TAF vs. Alternative Therapies

Parameter	FTC + TAF (Branded)	Tenofovir Disoproxil Fumarate (TDF)	Long-Acting Injectables (Cabotegravir + Rilpivirine)
Safety Profile	Superior for renal/bone health	Lower safety margin	No oral side effects, but injection site reactions
Resistance	Low, manageable	Higher resistance with long-term use	Minimal, but still under study
Adherence	High	Moderate	Very high due to dosing frequency
Cost	Higher	Lower	Higher

FAQs

1. How does the clinical efficacy of FTC + TAF compare to other HIV regimens?

FTC + TAF demonstrates over 95% viral suppression rates in clinical trials, comparable or superior to older TDF-based regimens, with improved safety. It benefits from once-daily dosing and a favorable side effect profile.

2. What are the recent regulatory updates concerning FTC + TAF?

Regulatory agencies like the FDA and EMA have approved various combination products, such as Biktarvy and Genvoya, incorporating FTC + TAF. New indications for PrEP and pediatric use are under review or recently approved.

3. What is the role of long-acting formulations in the future of FTC + TAF?

Long-acting injectables, such as cabotegravir and rilpivirine, are emerging options that may replace daily oral regimens for some patients, potentially expanding market share and increasing adherence.

4. How does the patent landscape affect the market outlook?

Patents on key formulations expire by mid-2020s, leading to an influx of generics that could reduce costs but also challenge profit margins for originators.

5. What are the major challenges facing the market growth of FTC + TAF?

Challenges include drug resistance development, pricing and affordability issues in low-income regions, regulatory delays for new formulations, and competition from novel drug classes.

Key Takeaways

• Clinical Progress: FTC + TAF remains highly effective, with ongoing trials emphasizing long-acting formulations and expanded indications, including pediatric use.
• Market Leadership: Gilead’s branded products dominate, leveraging their safety profile and efficacy.
• Growth Drivers: Increasing global HIV treatment and prevention, new formulations improving adherence, and expanding indications underpin positive market projections.
• Challenges: Patent expiries, competition from generics, resistance development, and pricing constraints pose risks.
• Future Outlook: The market is expected to grow at a CAGR of approximately 8.5–8.9% through 2030, driven by innovations and increased accessibility.

References

[1] UNAIDS. (2022). Global HIV & AIDS statistics — 2022 Fact Sheet.
[2] Gilead Sciences. (2020). DISCOVER Trial Results.
[3] European Medicines Agency. (2018). Regulatory decisions on HIV medication.
[4] MarketWatch. (2023). Global HIV drug market report.
[5] ClinicalTrials.gov. (2023). Active trials involving FTC + TAF.